PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för tirzepatide. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

36 hits

Bibliografisk träff 2022-05-17

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.

Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E.

Diabetologia · meta-analysis; systematic review; review-article; journal article · DOI 10.1007/s00125-022-05715-4

Bibliografisk träff 2022-03-25

Structural determinants of dual incretin receptor agonism by tirzepatide.

Sun B, Willard FS, Feng D, Alsina-Fernandez J, Chen Q, Vieth M, Ho JD, Showalter AD, Stutsman C, Ding L, Suter TM, Dunbar JD, Carpenter JW, Mohammed FA, Aihara E, Brown RA, Bueno AB, Emmerson PJ, Moyers JS, Kobilka TS, Coghlan MP, Kobilka BK, Sloop KW.

Proc Natl Acad Sci U S A · research-article; journal article · DOI 10.1073/pnas.2116506119

Bibliografisk träff 2022-03-01

Tirzepatide as an Insulin Sensitizer.

Ferrannini E.

J Clin Endocrinol Metab · comment; editorial · DOI 10.1210/clinem/dgab803

Bibliografisk träff 2022-01-01

An Introduction to Tirzepatide.

Bertsch T.

Clin Diabetes · research-article; journal article · DOI 10.2337/cd22-0038

Bibliografisk träff 2021-09-28

Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials.

Bhagavathula AS, Vidyasagar K, Tesfaye W.

Pharmaceuticals (Basel) · review-article; review; journal article · DOI 10.3390/ph14100991

Bibliografisk träff 2018-10-04

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.

Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A.

Lancet · clinical trial, phase ii; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(18)32260-8